Dr. Reddy's Laboratories achieved its highest-ever quarterly revenue for Q2, amounting to ₹1,299.15, which is a 2.12% increase.
Nuvama Institutional Equities appreciates Dr. Reddy's increased focus on developing complex high-value products but emphasizes the need for tangible updates on upcoming drug launches.
Similarly, Jefferies points out the absence of major product launches and the high selling, general, and administrative costs as factors that hinder Dr. Reddy's stock performance. Jefferies also maintains an 'underperform' rating and sets a price target of ₹1,130 for the drugmaker.